Italian drugmaker Newron Pharmaceuticals and EA Pharma, a subsidiary of Japan’s Eisai, today have entered into a license agreement to develop, manufacture and commercialize Newron’s evenamide in Japan and other designated Asian territories.
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
